Mesoblast Limited (ASX:MSB) Heart Failure Trial Selected for Presentation in Special Session of American Heart Association Annual Conference Melbourne, Australia on 15 August 2011

Melbourne, Aug 15, 2011 AEST (ABN Newswire) - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the "Clinical Science: Special Reports" session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference.

Results from the randomized, placebo-controlled Phase 2 trial of Mesoblast's allogeneic, or off-the-shelf, adult stem cell product, Revascor(TM), in patients with moderate-severe congestive heart failure will be presented by Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute, Houston.

The Phase 2 trial compared safety and efficacy outcomes in 45 patients who received a single injection of Revascor(TM) on top of standard-of-care with 15 patients who received standard-of-care alone. An important objective of the trial was to determine whether treatment with Revascor(TM) could positively impact on hard endpoints expected to be met in a subsequent Phase 3 trial for licensure approval by the United States Food and Drug Administration (FDA).

Mesoblast Chief Executive, Professor Silviu Itescu, said: "We are very pleased that the American Heart Association has selected our congestive heart failure trial of Revascor(TM) for presentation in the Special Reports session at their annual conference.

"Mesoblast is developing Revascor(TM) as an innovative therapy for a broad-based cardiovascular franchise, including the treatment of acute myocardial infarction and chronic refractory angina in addition to congestive heart failure.

"This forum provides an excellent opportunity for a wide audience of cardiovascular experts to be exposed to Mesoblast's proprietary cutting-edge technology and our robust clinical results," he added.

Contact

Julie Meldrum Corporate Communications Director T: +61-3-9639-6036 C: +61-419-228-128 Email:julie.meldrum@mesoblast.com